Elite in Congenital Afibrinogenemia

Claudia D. Khayat

Beirut, BA, LB 
Elite in Congenital Afibrinogenemia
Beirut, BA, LB 
OverviewLocationsClinical Research

Overview

Claudia Khayat practices in Beirut, Lebanon. Ms. Khayat is rated as an Elite expert by MediFind in the treatment of Congenital Afibrinogenemia. Her top areas of expertise are Congenital Afibrinogenemia, Familial Hypofibrinogenemia, Blood Clots, and Hemophilia A.

Her clinical research consists of co-authoring 12 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 4 articles and participated in 2 clinical trials in the study of Congenital Afibrinogenemia.

Gender
Female

Locations

Beirut, BA, Lebanon
Other Locations
Hotel Dieu, BA, Lebanon

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
A Prospective, Multicenter, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Human Plasma-derived Fibrinogen Concentrate (FIB Grifols) in Subjects With Congenital Afibrinogenaemia and Severe Hypofibrinogenemia Requiring Either On-demand Treatment for Acute Bleeding or Surgical Prophylaxis
Enrollment Status: Withdrawn
Publish Date: October 23, 2023
Intervention Type: Biological
Study Phase: Phase 3
Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenemia
Multicenter, Prospective, Open-Label, Single-Arm Trial to Evaluate the Pharmacokinetics, Efficacy, and Safety of Human Plasma-Derived Fibrinogen (FIB Grifols) in Patients With Congenital Afibrinogenemia
Enrollment Status: Completed
Publish Date: March 31, 2022
Intervention Type: Biological
Study Phase: Phase 1/Phase 2
View 1 Less Clinical Trial

12 Total Publications

Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.
Efficacy of regular prophylaxis with a plasma-derived von Willebrand factor/factor VIII concentrate with a 1:1 activity ratio in reducing heavy menstrual bleeding in girls/women with von Willebrand disease.
Journal: AJOG global reports
Published: June 19, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Khayat's expertise for a condition
ConditionClose
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile